Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria  by Rodicio, José L. et al.
Kidney International, Vol. 38 (1990), PP. 590—594
Influence of converting enzyme inhibition on glomerular
filtration rate and proteinuria
JosE L. RoDiclo, JosE M. ALCAZAR, and Luis M. RuIL0PE
Hypertensive Unit, Department of Nephrology, 12 Octubre Hospital and Complutense University of Madrid, Madrid, Spain
The progression of chronic renal failure is facilitated by the
presence of arterial hypertension. Antihypertensive therapy has
been shown to effectively protect the kidney from Continuous
functional derangement [I, 2]. The degree of proteinuria has
also been shown to be a prognostic factor for the progression of
chronic renal insufficiency [3, 4].
Recently, experimental [5, 6] and preliminary clinical data [71
have shown that converting enzyme inhibitors are effective in
slowing the progression of chronic renal failure. These drugs
also have the capacity to reduce glomerular proteinuria [8, 9],
and through this mechanism they also have the ability to change
the rate of progression of chronic renal failure.
On the other hand, the measurement of the progression of
chronic renal failure remains as a matter of debate [10, II]. The
usefulness of the slopes of the reciprocal of serum creatinine
has been questioned [10—121 and there seems to be general
agreement in the sense that sequential measurements of isotope
glomerular filtration rate or inulin clearance are the most
reliable methods to determine the rate of progression of chronic
renal failure.
This paper contains our experience on long-term effects of
the therapy with the angiotensin converting enzyme, captopril,
on the glomerular filtration rate and on the rate of progression of
renal insufficiency of patients with chronic renal failure and
arterial hypertension. Two previous publications of our group
[7, 9] contain the initial results of this study obtained during the
first year of follow-up in Group I and the first six months in
Group 2. Before switching their therapy to captopril, patients
were divided in two groups: Group 1, patients with primary
non-glomerular disease who exhibited a progressive decline in
renal function; their blood pressure was adequately controlled
by means of standard triple therapy. They were initially classi-
fied by the finding of a negative and significant slope of the
reciprocal of serum creatinine. Group 2 were patients diagnosed
by a renal biopsy as having a primary glomerular disease with
chronic renal failure, who presented with an adequate control of
their arterial hypertension with one or two standard drugs. The
long-term comparison of captopril versus standard therapy on
the progression of renal failure and on non-diabetic glomerular
proteinuria, as well as an evaluation of the different methods
employed to evaluate glomerular filtration rate are presented.
Methods
Group I comprised 10 patients, aged 46 to 60 years, five
males and five females, with histologically-proven chronic
interstitial nephropathy in five, chronic renal failure of un-
known etiology with small-sized kidneys, low range proteinuria
and without microhematuria in four, and adult polycystic kid-
ney disease in one.
All of them had been followed for at least 12 months period
during which they exhibited a progressive decline in the slope of
reciprocal of serum creatinine, an adequate control of blood
pressure with standard triple therapy (furosemide 40 to 180
mg/day, propranolol 120 to 300 mg/day, and hydralazine 50 to
200 mg/day) and had not changed their dietary habits for at least
eight months.
The Group 2 included 20 patients, aged between 20 and 61
years, 14 males and 6 females, who had been diagnosed by renal
biopsy as having primary glomerular disease (IgA nephropathy
in 8, focal and segmental glomerulosclerosis in 7, mesangiocap-
illary glomerulonephritis in 2, membranous nephropathy in 2,
and rapidly progressive glomerulonephritis in I). All were being
treated with one or two antihypertensive drugs (furosemide 40
to 120 mg/day, propranolol 120 to 200 mg/day). The patients
were divided for analysis of the data in two subgroups accord-
ing to the presence of a daily proteinuria in excess (Group 2a) or
below (Group 2b) 3 g. Patients were encouraged to continue
with their previous dietary habits. After obtaining baseline
clinical and laboratory data the patients were switched to the
CEI captopril, in doses adequate to control hypertension to
levels similar to those while on standard therapy. After 48 to 72
hours of discontinuation of the standard therapy, captopril was
initiated at a dose of 25 mg twice daily. The dose of captopril
was titrated weekly thereafter.
The effect of captopril on renal hemodynamics was deter-
mined by measuring the C1, and CPAH at baseline, and after 3
months and every 6 months during the therapy with captopril.
In addition the estimated slope of 1/Cr plotted versus time was
obtained and calculated in Group 1 for the 12 months before
initiation of captopril and yearly thereafter. The values of serum
creatinine and creatinine clearance were obtained monthly
during all the follow-ups in every patient, together with the
variations of blood pressure (BP), body weight and other
laboratory parameters. Plasma renin activity (PRA) and plasma
aldosterone (PA) values were estimated with the same fre-
quency as inulin and PAH clearances. BP was measured by two
trained observers with a standard mercury sphygmomanome-© 1990 by the International Society of Nephrology
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ter. Systolic (first phase) and diastolic (fifth phase) BP were
measured in the sitting position in an out-patient clinic.
The methods utilized for the measurement of C1, CPAH, PRA
and PA, and the other biochemical parameters have been
previously described [7, 9].
All data were analyzed by repeated measure analysis of
variance (ANOVA) followed by a Dunnett test and by regres-
sion analysis using standard formulae. Statistical significance
was defined as P < 0.05.
Results
Group I
As can be seen in Figure 1, the control of blood pressure was
similar when values from standard triple therapy were com-
pared with those obtained with captopril alone, Meanwhile,
inulin and para-aminohippurate clearances increased signifi-
cantly during the first three months. This was probably attrib-
utable to the withdrawal of triple therapy, although a beneficial
effect of captopril cannot be excluded. The initial improvement
remained throughout 18 months, and values similar to those
obtained at the baseline were found thereafter.
The variations of PRA and PA were as expected: an increase
of the first and a fall of the second. Plasma potassium and the
urinary excretion of urea persisted within similar levels, indi-
cating that the renal handling of potassium remained within
acceptable limits and that the protein intake in the diet was
stable. Table 1 shows the evolution of the reciprocal of serum
creatinine plotted versus time during follow-up before and after
the change to the ACE inhibitor. The slope changed signifi-
cantly during the first year and was less negative during the
second and third years.
A positive correlation was found between l/Crs and C1, C.
and CPAH. C10 also correlated with Cc and CPAH (Table 2).
Group 2
Figure 2 and Figure 3 show the data obtained in patients
included in Group 2 divided according to the level of 24-hour
proteinuria as previously stated. An increase in C1 and CPAH
was observed in both subgroups of patients after three months
of captopril therapy. The improvement was maintained only in
those patients exhibiting initial proteinuria levels below the
nephrotic range. Serum albumin increased and serum choles-
terol decreased in subgroup 2a but not in Group 2b. PRA, PA
and potassium and urine urea excretion exhibited changes
similar to those observed in Group 1.
Proteinuria decreased significantly in Group 2a after the first
month of therapy and remained within similar levels during the
two years of follow-up. In subgroup 2b the level of proteinuria
fell significantly only during the second year of follow-up (Fig.
4).
A positive correlation was also found between the values of
1/Crs and C1, Cr and CPAH in both groups of patients. C1
correlated with Cr and CPAH (Table 3). A negative and
significant correlation (r =
—0.250, P < 0.01) was found
between 1/Crs and proteinuria in those patients with baseline
proteinuria above 3 g/24 hr but not in the others. On the other
hand, proteinuria did not correlate with Cr or C1.
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Fig. 1. Values (5EM and P) of BP, GFR, RPF, PRA and PA daring
standard therapy (Basal) and after captopril therapy in patients of
Group 1. Symbols are: A: (U) SBP; (D) DBP; P = NS; B: (U) C10, ()
Ccr, (0) CPAH; **D < o,o, *P < 0.05; C: (U) PRA; (D) aldosterone;
**p < 0.01, *p < 0.05.
Discussion
Comparison of captopril with standard triple therapy
The group of ten patients whose arterial hypertension was
controlled with triple drug therapy exhibited an increase of C10
and CPAH by approximately 24% to 30% during the first three
months of captopril therapy. This change took place despite
similar degrees of BP control by both therapeutic regimes.
Subsequently both parameters remained significantly elevated
until the eighteenth month of captopril therapy, and were not
different from baseline values thereafter. Although the initial
changes could be ascribed to the withdrawal of standard ther-
apy [13, 14], the sustained beneficial effect on renal hemody-
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Standard
therapy
(basal)
12
months
Captopril therapy
12
months
24
months
36
months
Mean
SEM
—0.0067
0.0013
÷O.003a
0.001
—0.0015
0.0134
—0.0011
0.0034
a p < 0.01
Correlation r P N
l/Crs — C 0.827 <0.01 80
1/Crs — Cr 0.828 <0.01 360
1/Crs
C1,, —
— CPAH
Ccr
0.742
0.935
<0.01
<0.01
80
80
C1,, — 0.931 <0.01 80
namics probably depends on the hemodynamic effect of capto-
pril [15}. Other non-hemodinamically mediated factors could
also have participated in the improvement of renal function
[16].
Our results are in accordance with the statement that inulin
clearance is the most adequate method, together with isotopic
methods, to estimate the rate of progression of renal failure [10,
lii. Creatinine measurements in plasma and urine have been
considered as misleading in evaluating progression [11]. Nev-
ertheless, in our experience the measurement of serum creati-
nine and its renal clearance seems to be adequate to estimate
the rate of progression, at least, if the conditions in which our
study was performed are provided. It is at present unclear
whether changes in l/Crs over time represent a precise and
consistent method of measurement, particularly when patients
are subjected to dietary maneuvers that can influence creatinine
production [10, 11]. In our patients, the urinary urea excretion
did not change during the follow-up, indicating that roughly
their protein intake remained stable. This fact, together with the
good correlation of 1/Crs with inulin clearance permits a con-
sideration that ACE inhibition arrested the progression of renal
failure during the period of the study.
Effect on proteinuria
ACE inhibitors have been shown to reduce diabetic [17] and
nondiabetic [8, 9] glomerular proteinuria. Proteinuria is a factor
that indicates a poor prognosis for the progression of renal
failure [3, 4]. The diminution of the rate of protein excretion in
urine could be a contributing factor in slowing the progression
of renal failure. In fact, the reduction of microalbuminuria has
been accompanied by an improvement in renal function in
diabetic patients [18—20].
We have found that captopril therapy was able to improve
renal function and decrease proteinuria in patients with primary
renal disease. Nevertheless, no clear correlation was found
between proteinuria and glomerular filtration rate measured
either by creatinine or inulin clearances. The improvement in
renal function remained longer in those patients exhibiting the
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Fig. 2. Values (SEM and P) ofGFR, RPF, PRA, PA, serum albumin
and serum cholesterol during standard therapy (Basal) and after
captopril therapy in patients of Group 2a. Symbols are: A: (•) C10, ()
Ccr; (0) CPAH, 'P < 0.01, P < 0.05; B (U) PRA, () aldosterone,
< 0.001, < 0.01, P < 0.05; C (U) albumin, () cholesterol,
< 0.01, P < 0.05.
lower baseline values of proteinuria. This seems to be in
accordance with the poorer prognosis of those patients exhib-
iting higher levels of urinary protein excretion [3, 4].
In glomerular patient group the measurement of inulin clear-
ance also seemed to be the most adequate method for evaluat-
ing renal function, although creatinine clearance behaved in a
quite similar fashion.
In summary, in our experience, provided that protein intake
remains roughly unchanged, and patients are maintained at
equal levels of blood pressure control, converting enzyme
inhibition seems to have advantages over standard therapy to
Table 1. Slope of the linear regression between the reciprocal of
serum creatinine versus time in patients of Group I
Table 2. Correlation between different parameters of renal function
in patients of Group I
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Fig. 4. Twenty-four hour protein excretion during standard therapy
(Basal) and after captopril therapy in patients of Groups 2a and 2b.
Symbols are: (U) Group 2A; (0) Group 2b; < 0.001; * < 0.05.
Table 3. Correlations between different parameters of renal function
in patients of Group 2
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Correlation
Group 2a Group 2b
r P N r P N
1/Crs — C1l/Crs — Cr
0.906
0.901
<0.01
<0.01
72
307
0.863
0.830
<0.01
<0.01
42
144
1/Cr — CPAH 0.895 <0.01 72 0.886 <0.01 42
— Ccr 0.980 <0.01 72 NS NS NS
C — CPAH 0.937 <0.01 72 0.959 <0.01 42
Basal 3 6 12 18 24
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